CELL THERAPEUTICS INC | 2013 | FY | 3


The total initial purchase consideration was as follows (in thousands):

 

Cash

   $  15,000   

Fair value of Series 16 Preferred Stock

     11,344   

Transaction costs

     2,764   
  

 

 

 

Total initial purchase consideration

   $ 29,108   
  

 

 

 

us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock